Schering-Plough Reports Top-Line Results of the I... ( First Large Study Comparing Leading...)

Schering-Plough Reports Top-Line Results of the IDEAL Study

Date:1/14/2008

First Large Study Comparing Leading Hepatitis C Therapies Shows Similar Sustained Response Rates; Fewer Patients Relapsed Following PEGINTRON

Combination Therapy

KENILWORTH, N.J., Jan. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP), a leader in hepatitis research, today reported top- line results of the IDEAL study, the first large, randomized, clinical study comparing the leading therapies for chronic hepatitis C: PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy vs. Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP) combination therapy,(1) as well as a lower dose of PEGINTRON in an investigational combination regimen. The results showed that sustained virologic response (SVR),(2) the primary endpoint of the study, was similar for the two leading combination therapies for hepatitis C; and that using a lower dose of PEGINTRON with REBETOL also resulted in a similar SVR. The study also showed that fewer patients treated with both PEGINTRON regimens relapsed after the end of treatment compared to those receiving Pegasys and Copegus.

In the IDEAL (Individualized Dosing Efficacy vs. Flat Dosing to Assess optimaL pegylated interferon therapy) study, both PEGINTRON regimens utilized investigational weight-based ribavirin dosing. The three treatment regimens studied were:

(1) PEGINTRON 1.5 mcg/kg/week and REBETOL 800-1,400 mg/day;

(2) PEGINTRON 1.0 mcg/kg/week and REBETOL 800-1,400 mg/day; and

(3) Pegasys 180 mcg/week and Copegus 1,000-1,200 mg/day

In the study, 3,070 previously untreated U.S. patients with HCV genotype 1, the most common form of the virus worldwide and most difficult to treat, were
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
2. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
3. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Second Thoughts about Fluoride, Reports Scientific American
6. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
9. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
10. Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM)
11. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial

Post Your Comments:

(Date:5/17/2013)... CHAPEL HILL, N.C. , May 17, 2013 ... on how organizations communicate internally. Faced with a ... adjust their strategies and tactics for communicating with ... the effectiveness of all the strategies, tactics and ... In a new study, Best ...

(Date:5/17/2013)... 17, 2013 Sony Biotechnology Inc. ("Sony") today announced ... (SP6800). Sony will be exhibiting and taking orders for ... at the San Diego Convention ... from May 20 - 22. The ... commercial audio-visual technologies into new and novel functionalities for ...

(Date:5/17/2013)... TechAtlas Group has announced the release of ... for the Chronic Kidney Disease (CKD) market. This ... drugs and devices currently on the market and ... (Logo: http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) ... renal denervation , diabetic nephropathy - antifibrotics ...

Breaking Medicine Technology:Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness 2 Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2 TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2

[0] Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness [0] Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color [0] TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map

... PARK, Calif., Sept. 14 Praxis EMR has submitted its ... EMRs to apply for HITECH certification in the country. Under ... in federal incentives if they can demonstrate "meaningful use" of ... the U.S. Department of Health and Human Services to test ...

... Reportlinker.com announces that a new market research ... Autistic Disorder - Pipeline Assessment and Market ... Autistic Disorder - Pipeline ... SummaryGlobalData, the industry analysis specialist, has released ...

Cached Medicine Technology:Praxis EMR Among First to Apply for HITECH Certification 2 Reportlinker Adds Autistic Disorder - Pipeline Assessment and Market Forecasts to 2017 2 Reportlinker Adds Autistic Disorder - Pipeline Assessment and Market Forecasts to 2017 3

Praxis EMR Among First to Apply for HITECH Certification Reportlinker Adds Autistic Disorder - Pipeline Assessment and Market Forecasts to 2017

(Date:5/19/2013)... 2013 These molecular diagnostics market ... Spain, Japan, Italy, Germany and France:, ... laboratory practice, as well as key economic, regulatory, ... impact during the next five years. , ... technologies, test formats, detection methodologies, trends in testing ...

(Date:5/19/2013)... May 19, 2013 Americans live closer ... the newest American Veterinary Medical Association (AVMA) U.S. Pet ... dog owners consider their dog a member of the ... said as much five years earlier. , According to ... of the national income dedicated to pets has increased ...

(Date:5/19/2013)... Vegas Hotel Escapes, the premier Las ... launch it's all new vacation packages for the upcoming ... Consumers traveling to Las Vegas will be pleased to ... website. Travelers will be pleased to know that VegasHotelEscapes.com ... Vegas Hotel Escapes specializes in helping consumers Las ...

(Date:5/19/2013)... Passages Malibu, the leading non-12 step, holistic, and ... the launch of a “Sobriety, Health, and Wellness” survey ... “We are always looking for new ways to engage ... regarding sobriety, what’s working for people, and what isn’t,” ... Passages Addiction Treatment Centers located in Malibu and ...

(Date:5/19/2013)... HealthEconomics.Com , the global leader ... unveil a new and exciting service: HE-Xpo: a media-rich, ... array of real-time communication tools to expand their digital ... , HE-Xpo is powered by OnStream Media’s ... feel of being at a physical trade show, all ...

Breaking Medicine News(10 mins):Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2 Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3 Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4 Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2 Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3 Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 2 Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 3 Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2 Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3

[0] Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com [0] Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing [0] VegasHotelEscapes.com Announces Special Vegas Packages For Billboard Music Awards [0] Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey [0] HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access

... Programs During the Quarter, PALO ALTO, Calif., Nov. ... announced financial results for,the quarter ended September 30, 2007. ... of 2007 was $19.4,million, compared to net income of ... in the quarter ended September 30, 2006 included $31.6,million ...

... NEW YORK, Nov. 6 Weight Watchers,International, Inc. (NYSE: ... 29, 2007. Third Quarter 2007 Results For the ... to $337.5 million, up from $284.8 million in the third ... in the third quarter,of 2007 to $0.62 versus $0.52 in ...

... looks at hospital discharge rates in Raleigh and 6 ... ... County EMS has,participated in a seven-city study on the impact of new ... Heart,Association,s new 2005 CPR guidelines, according to the study authors in a,presentation ...

... rates in Cypress Creek and ... 6 other cities, ... in a seven-city study on the impact of new CPR techniques,the results ... CPR guidelines, according to the study authors in a,presentation at the AHA,s ...

... with Cardiac Resynchronization Therapy, researchers say , TUESDAY, Nov. ... a device that synchronizes pumping in the heart,s ventricles ... The results were presented Tuesday at a late-breaking clinical ... in Orlando, Fla., and were expected to be published ...

... Institute of Allergy and Infectious Diseases (NIAID), part of ... to strengthen and expand its nationwide group of institutions ... for infectious diseases. In addition to increasing the number ... Vaccine and Treatment Evaluation Units (VTEUs) to carry out ...

Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results Weight Watchers Announces Third Quarter 2007 Results Raleigh in National Study, Shows Survival to Hospital Discharge After Cardiac Arrest Doubles With Improved CPR and Impedance Threshold Device Cypress Creek in National Study, Shows Survival To Hospital Discharge After Cardiac Arrest Doubles with Improved CPR and Impedance Threshold Device Cardiac Device Won't Help Some Heart Failure Patients NIAID strengthens and expands Vaccine and Treatment Evaluation Units

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Xylocaine White Blood Cell Count Western Equine Encephalitis Antibody, IgM by IFA, Serum West Nile Virus RNA by RT-PCR